论文部分内容阅读
Background Accumulating evidence suggests that hypoglycaemic agents influence lung cancer risk in patients with diabetes.It remains to be fully elucidated whether conventional hypoglycaemic agents (metformin, sulfonylureas, thiazolidinediones (TZDs) or insulin) affect lung cancer incidence in patients with diabetes.